As the world's ninth most common cause of cancer-related death, Bladder Cancer affects approximately 4,00,000+ people globally and is more common in men than women.
A radical cystectomy is currently the gold standard of treatment for MIBC - Muscle-invasive Bladder Cancer and some high grade NMIC - Non-muscle-invasive Bladder Cancer. While open radical cystectomy was being commonly performed for localized Bladder Cancer, the entry of robotic platforms a few years back paved the way for a new future.
Let’s have a quick understanding of the key factors contributing to the growing popularity of robotic surgery:
Robotic surgery has proven to be a boon for patients undergoing removal of bladder for Bladder Cancer. It is particularly advantageous over laparoscopy for intracorporeal diversions during cystectomy wherein the urinary pathway is reconstructed in a minimal invasive way with much ease and precision. The addition of firefly technology even enables the surgeon to make sure that the blood supply of tissues is adequately preserved at the margins during anastomosis.
At Medanta, we strive to provide state-of-the-art care to our patients with the latest robotic technology along with adherence to principles of ERAS( enhanced recovery after surgery). The team of experts is extensively involved in research and practices evidence-based medicine in order to achieve the best possible outcomes for the patient.